Literature DB >> 23095141

Testing and interpreting measures of ovarian reserve: a committee opinion.

.   

Abstract

Currently, there is no uniformly accepted definition of decreased ovarian reserve (DOR), as the term may refer to three related but distinctly different outcomes: oocyte quality, oocyte quantity, or reproductive potential. Available evidence concerning the performance of ovarian reserve tests is limited by small sample sizes, heterogeneity among study design, analyses and outcomes, and the lack of validated outcome measures.
Copyright © 2012 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2012        PMID： 23095141     DOI： 10.1016/j.fertnstert.2012.09.036

Source DB:  PubMed          Journal:  Fertil Steril        ISSN： 0015-0282            Impact factor:   7.329


  35 in total

1.  Diminished ovarian reserve in the United States assisted reproductive technology population: diagnostic trends among 181,536 cycles from the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System.

Authors:  Kate Devine; Sunni L Mumford; Mae Wu; Alan H DeCherney; Micah J Hill; Anthony Propst
Journal:  Fertil Steril       Date:  2015-06-11       Impact factor: 7.329

2.  BRCA1 germline mutations may be associated with reduced ovarian reserve.

Authors:  Erica T Wang; Margareta D Pisarska; Catherine Bresee; Yii-Der Ida Chen; Jenny Lester; Yalda Afshar; Carolyn Alexander; Beth Y Karlan
Journal:  Fertil Steril       Date:  2014-09-23       Impact factor: 7.329

3.  Serum antimüllerian hormone measurements with second generation assay at two distinct menstrual cycle phases for prediction of cycle cancellation, pregnancy and live birth after in vitro fertilization.

Authors:  Carolina P Rezende; Ana L Rocha; Cynthia Dela Cruz; Lavinia E Borges; Helen L Del Puerto; Fernando M Reis
Journal:  J Assist Reprod Genet       Date:  2014-07-12       Impact factor: 3.412

4.  A novel mathematical model of true ovarian reserve assessment based on predicted probability of poor ovarian response: a retrospective cohort study.

Authors:  Huiyu Xu; Guoshuang Feng; Haiyan Wang; Yong Han; Rui Yang; Ying Song; Lixue Chen; Li Shi; Meng Qian Zhang; Rong Li; Jie Qiao
Journal:  J Assist Reprod Genet       Date:  2020-04-21       Impact factor: 3.412

5.  Knowledge of ovarian reserve and reproductive choices.

Authors:  Erum Azhar; David B Seifer; Katherine Melzer; Ahmed Ahmed; Jeremy Weedon; Howard Minkoff
Journal:  J Assist Reprod Genet       Date:  2015-01-18       Impact factor: 3.412

6.  Antimüllerian hormone and antral follicle count are lower in female cancer survivors and healthy women taking hormonal contraception.

Authors:  Lauren N C Johnson; Mary D Sammel; Katherine E Dillon; Lara Lechtenberg; Allison Schanne; Clarisa R Gracia
Journal:  Fertil Steril       Date:  2014-06-14       Impact factor: 7.329

7.  Determining an anti-Mullerian hormone cutoff level to predict clinical pregnancy following in vitro fertilization in women with severely diminished ovarian reserve.

Authors:  Zaher Merhi; Athena Zapantis; Dara S Berger; Sangita K Jindal
Journal:  J Assist Reprod Genet       Date:  2013-08-21       Impact factor: 3.412

8.  Is Anti-Müllerian Hormone Associated With Fecundability? Findings From the EAGeR Trial.

Authors:  Shvetha M Zarek; Emily M Mitchell; Lindsey A Sjaarda; Sunni L Mumford; Robert M Silver; Joseph B Stanford; Noya Galai; Mark V White; Karen C Schliep; Alan H DeCherney; Enrique F Schisterman
Journal:  J Clin Endocrinol Metab       Date:  2015-09-25       Impact factor: 5.958

9.  Diminished ovarian reserve in Behçet's disease patients.

Authors:  Andrea R S Mont'Alverne; Lucas Y S Yamakami; Célio R Gonçalves; Edmund C Baracat; Eloisa Bonfá; Clovis A Silva
Journal:  Clin Rheumatol       Date:  2014-05-31       Impact factor: 2.980

10.  Antimüllerian hormone and pregnancy loss from the Effects of Aspirin in Gestation and Reproduction trial.

Authors:  Shvetha M Zarek; Emily M Mitchell; Lindsey A Sjaarda; Sunni L Mumford; Robert M Silver; Joseph B Stanford; Noya Galai; Karen C Schliep; Rose G Radin; Torie C Plowden; Alan H DeCherney; Enrique F Schisterman
Journal:  Fertil Steril       Date:  2015-12-17       Impact factor: 7.329
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.